Sex-Related Differences in Immune Response and Symptomatic Manifestations to Infection with <i>Leishmania</i> Species.
Lockard, Ryan D; Wilson, Mary E; Rodríguez, Nilda E.
J Immunol Res
; 2019: 4103819, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30756088
Expression profiling of Sudanese visceral leishmaniasis patients pre- and post-treatment with sodium stibogluconate.
[COMPARISON OF THE EFFECTIVENESS OF DRUGS FOR THE TREATMENT OF CUTANEOUS LEISHMANIASIS IN VITRO].
Chemotherapy of leishmaniasis: present challenges.
Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy.
Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B.
Visceral leishmaniasis with cutaneous symptoms in a patient treated with infliximab followed by fatal consequences.
Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India.
Susceptibility to leishmaniasis is affected by host SLC11A1 gene polymorphisms: a systematic review and meta-analysis.
FLI1 gene influences lesion size and skin test may predict therapeutic response in cutaneous leishmaniasis.